Neurocrine Biosciences Inc
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +35.9% | -38.7% | +5.0% | -13.2% | +182.7% | -56.2% | +670.7% | -38.8% | +45.5% | -68.3% | -96.9% | +224.8% | -25.7% | +1,034.5% | +131.1% | -31.4% | -94.5% | -100.0% | – | -24.1% | +977.5% | +179.2% | +74.7% | +32.7% | +8.4% | +31.3% | +26.8% | +24.8% | +21.4% | |
| – | – | – | – | – | – | +432.9% | +63.8% | -32.8% | +6.5% | -4.6% | -22.1% | -36.1% | -31.9% | -4.2% | -3.0% | -72.2% | +19.0% | +4.3% | +134.7% | +6.2% | -96.5% | +289.9% | +51.4% | +36.5% | +41.6% | +62.2% | +71.1% | -14.4% | +53.2% | |
| – | +35.6% | -35.4% | +6.8% | -11.2% | +145.7% | -56.2% | +670.7% | -38.8% | +45.5% | -68.3% | -96.9% | +224.8% | -25.7% | +1,034.5% | +131.1% | -46.3% | -126.2% | – | – | -24.1% | +969.1% | +178.3% | +74.9% | +32.7% | +8.1% | +30.9% | +26.1% | +25.7% | +21.0% | |
| – | +57.9% | +9.5% | +33.9% | +37.8% | +84.6% | +46.7% | +62.7% | -35.1% | -7.3% | -8.4% | -16.1% | -32.3% | -39.3% | -7.6% | -0.6% | +20.1% | +5.6% | +18.3% | +75.5% | +15.7% | -2.6% | +74.8% | +24.6% | +37.5% | +19.3% | +41.4% | +21.8% | +29.4% | +38.9% | |
| – | +54.1% | +15.8% | +13.6% | +32.8% | +9.0% | +17.2% | +61.9% | +9.0% | +88.6% | +29.6% | -31.7% | -46.0% | -26.7% | +8.4% | -22.0% | +7.2% | -0.7% | +34.7% | +80.6% | +109.6% | +149.6% | +46.5% | +42.2% | +22.4% | +34.6% | +29.0% | +13.1% | -4.2% | +41.7% | |
| – | +55.5% | +11.9% | +28.9% | +35.0% | +62.5% | +42.9% | +62.6% | -30.5% | +8.3% | +2.4% | +39.9% | -57.2% | -38.0% | -16.6% | -7.9% | +18.9% | +1.8% | +22.5% | +76.9% | +42.5% | +79.7% | +40.4% | +73.0% | +23.2% | +16.5% | +19.7% | +31.2% | +9.7% | +25.0% | |
| – | -82.8% | -2,580.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | -95.7% | -3,530.8% | – | – | – | – | – | +96.0% | +125.4% | -37.1% | +142.9% | +0.8% | +127.4% | +8.5% | |
| – | – | – | – | – | – | – | +6.4% | +280.0% | +112.0% | -10.5% | +5.4% | +79.1% | +0.0% | +0.0% | -100.0% | – | – | – | – | – | – | +56.4% | +4.8% | +2.5% | -21.3% | -72.5% | -35.2% | +2,652.2% | – | |
| – | -13.1% | -473.6% | – | – | – | – | – | – | – | – | – | – | – | – | – | -86.6% | -1,017.2% | – | – | – | – | – | +112.9% | +129.5% | -5.0% | +110.9% | +55.3% | +46.3% | +45.1% | |
| – | +0.0% | +3,700.0% | -140.8% | – | -60.3% | -7,665.8% | – | -50.0% | – | – | – | – | -86.8% | – | – | – | – | – | – | – | – | -95.7% | +1,201.4% | -3,264.2% | – | +403.4% | +38.7% | +75.6% | +56.7% | |
| – | -13.6% | -492.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | -86.6% | -1,017.2% | – | – | – | – | – | +75.3% | +1,000.8% | -78.0% | +72.4% | +61.6% | +36.7% | +40.2% | |
| – | +260.0% | -694.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | -93.9% | -2,428.1% | – | – | – | – | – | +109.9% | +72.4% | -6.8% | +91.6% | +57.3% | +53.7% | +4.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.